Effect of obesity on platelet reactivity and response to low-dose aspirin

Insufficient platelet function suppression by aspirin is a predictor of cardiovascular events in high-risk patients. The authors assessed the impact of obesity on platelet responsiveness before and after 2 weeks of aspirin 81 mg/d in 2014 people. Obese individuals had greater baseline platelet reactivity. Comparing obese and nonobese individuals after aspirin therapy, results for aggregometry to collagen were 6.7 vs 6.1 ohms, P=008; aggregometry to adenosine diphosphate were 13.1 vs 11.8 ohms,P<0001; aggregometry to arachidonic acid (AA) were 4.9% vs 8.3% nonzero aggregation, P=002; urinary excretion of 11-dehydro-thromboxane B2 (Tx-M) were 4.9% vs 8.3% nonzero aggregation, P=002; and aspirin resistance were 26.% vs 20.5%, P=002; respectively. These remained significantly different for AA aggregation and Tx-M excretion after adjustment for covariates. Obese individuals have greater native platelet reactivity and retain greater reactivity after suppression by aspirin.Prev Cardiol.